Abstract
Multiple sclerosis (MS) is a disease of young adults resulting in disability if left untreated. The pathogenesis involves immunopathological events including, on the one hand, demyelination and, on the other hand, axonal degeneration in the central nervous system.
The current therapeutic options targeting the pathogenetic events are acute relapse treatment with high-dose corticosteroids and long-term immunomodulatory treatment with biological agents- interferon β and glatiramer acetate as first-line therapies and natalizumab or motoxantrone as second-line escalation therapies. Fingolimod was recently registered by the FDA as the first oral therapy for relapsing-remitting MS.